---
schema_version: "secwatch.filing_event.v1"
accession: "0001576885-25-000072"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2025-06-05T23:59:59+00:00"
generated_at: "2026-05-19T21:51:57.115153+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.05
calibrated_materiality_score: 0.05
confidence: "high"
source: SEC EDGAR
---

# Acumen shareholders elect three Class I directors, ratify EY as auditor

## Summary
- Elected Kimberlee C. Drapkin, Jeffrey Ives, and Sean Stalfort as Class I directors until 2028 with ~30M votes each; ~17.5M broker non-votes.
- Ratified Ernst & Young as independent auditor for FY2025: 51.4M for, 118,735 against, 35,514 abstain.
- Approximately 85% of outstanding shares (51.5M of 60.6M) were present or represented at the meeting.

## SEC filing metadata
- accession: 0001576885-25-000072
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2025-06-05T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.05
- calibrated_materiality_score: 0.05
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000157688525000072/0001576885-25-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000157688525000072/abos-20250604.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576885-25-000072
- JSON: https://secwatch.observer/filing/0001576885-25-000072.json
- Plain text: https://secwatch.observer/filing/0001576885-25-000072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.